CGRP — calcitonin gene-related peptide — is the migraine target that opened the modern migraine therapeutics market (erenumab, fremanezumab, galcanezumab, and the gepant small molecules). Coverage on this site has shifted recently as GLP-1 drugs have shown migraine benefit in head-to-head and registry analyses.
The most cited 2026 read: AAN 2026 reported that GLP-1 agonists cut migraine ED visits 10% and hospitalizations 14% versus topiramate in a 22,000-patient comparative study, plus a 42% reduction in CGRP monoclonal antibody starts. The overlap raises questions about whether GLP-1s, gepants, and CGRP antibodies sit in additive or competitive positions for chronic migraine. On October 1, 2026, Lundbeck reported that in its open-label Phase 4 THRIVE trial, 60% of 164 adults whose migraine had responded inadequately to one prior CGRP-targeting preventive rated themselves much or very much improved after 24 weeks on Vyepti (eptinezumab).
Stories here cover the migraine peptide pipeline and the GLP-1 spillover. See #migraine for the indication and #gepants for small-molecule CGRP antagonists.
Lundbeck reported headline results on Thursday, October 1, 2026 from THRIVE, an open-label Phase 4 trial of Vyepti (eptinezumab), an antibody against the neuropeptide CGRP, in 164 adults with at least eight monthly migraine days whose migraine had responded inadequately to one prior CGRP-targeting preventive, either a subcutaneous antibody or a gepant. Patients received 100 mg at baseline and 300 mg at week 12; at week 24, 60% rated themselves much or very much improved on the Patient Global Impression of Change scale, up from 44% at week 12, and 84% completed the study. There was no placebo group, and Lundbeck said no new safety signals were seen.
A presentation at the American Academy of Neurology 2026 meeting (closing April 22) reported that in 10,997 chronic migraine patients initiating GLP-1 agonists versus an equal topiramate cohort, GLP-1 users were 10% less likely to visit the ED (23.7% vs 26.4%), 14% less likely to be hospitalized, 42% less likely to start CGRP monoclonal antibodies, and 48% less likely to start valproate over 12 months — adding migraine to the growing list of GLP-1 secondary benefits.
New data shows the first oral CGRP antagonist ubrogepant demonstrates better efficacy when administered during mild pain rather than waiting for moderate-to-severe migraine pain.
Retrospective study found combining CGRP monoclonal antibodies with gepants is a safe and well-tolerated dual-mechanism migraine prevention approach.
Retrospective cohort study showed significant migraine frequency reduction with favorable safety for patients with comorbid MS taking CGRP-targeted treatments.